Diabetes in writingFindings from a clinical trial comparing Victoza (liraglutide 1.8 mg) and sitagliptin (100 mg), both in combination with metformin, demonstrated that switching from sitagliptin to liraglutide provided superior HbA1c reductions compared to continuing with sitagliptin treatment in adults with type 2 diabetes.

The results were taken from the LIRA-SWITCH trial and were presented at the Endocrine Society’s 98th Annual Meeting and Expo (ENDO 2016) in Boston, Massachusetts.

The 26-week LIRA-SWITCH trial assessed the efficacy and safety of liraglutide as an add-on to metformin in 407 adults with type 2 diabetes who switched from sitagliptin. Of the 407 adults uncontrolled on sitagliptin at week 26, those who switched to liraglutide (n=203) achieved a superior reduction in HbA1c compared to those who continued their sitagliptin treatment (n=204).

Additionally, adults who switched to liraglutide experienced significantly greater body weight reductions compared with those who continued with their sitagliptin dose.

"The LIRA-SWITCH trial results provide valuable insight that adults uncontrolled on sitagliptin may achieve a superior HbA1c reduction with liraglutide 1.8 mg vs continuing on sitagliptin treatment,” said Dr Maximo Maislos, Director of Western Negev Mobile Diabetes Clinic Program, and Diabetes and Metabolism, Ben-Gurion University FOHS, Beer Sheva-Israel and investigator of the LIRA-SWITCH trial. “These findings are valuable as there is limited clinical evidence to guide treatment strategy when people with type 2 diabetes are uncontrolled on second-line therapy."

However, adverse events were more common in the liraglutide group compared to the sitagliptin group, with gastrointestinal side effects, including nausea and diarrhoea, more frequent with liraglutide. There were no reports of severe hypoglycaemia and no reports of confirmed nocturnal hypoglycaemia.

The 26-week LIRA-SWITCH trial was a randomised, double-blind, double-dummy, active-controlled trial involving 407 adults with type 2 diabetes not achieving adequate glycaemic control on sitagliptin as add-on to metformin.

Trial participants were previously treated with stable doses of sitagliptin (100 mg daily) and metformin (≥1500 mg daily or maximum tolerated dose ≥1000 mg daily) for ≥90 days. Participants were randomised 1:1 to switch to liraglutide 1.8 mg or continue sitagliptin 100 mg, both in combination with metformin.